PTCT
PTC Therapeutics, Inc.
NASDAQ · USHealthcareBiotechnology
$78.01-0.74%
Price as of Jul 20, 2026
PTCT profitability
PTC Therapeutics, Inc. profitability
Margins, returns on capital and operating-efficiency metrics from the latest trailing period.
Margins
- Gross margin
- 77.8%
- EBITDA margin
- -14.5%
- EBIT margin
- -8.2%
- Net margin
- -22.6%
- Free cash flow margin
- -31.9%
Returns
- Return on equity
- 103.5%
- Return on assets
- -6.5%
- Return on invested capital
- -31.5%
- Asset turnover
- 0.29x
Cash efficiency
- Cash from operations
- -$217.9M
- Cash per share
- $23
Latest available reported and market-derived figures. A dash means the source dataset does not currently cover that metric; it does not imply a zero value.